GAP-134

• CAT Number: I005610
• CAS Number: 943134-39-2
• Molecular Formula: C14H17N3O4
• Molecular Weight: 291.3
• Purity: ≥95%
• Synonyms: 1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
• Target: Gap Junction Protein
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid
• InChI: InChI=1S/C14H17N3O4/c15-7-12(18)17-8-10(6-11(17)14(20)21)16-13(19)9-4-2-1-3-5-9/h1-5,10-11H,6-8,15H2,(H,16,19)(H,20,21)/t10-,11+/m1/s1
• InChIKey: BIZKIHUJGMSVFD-MNOVXSKESA-N
• SMILES: C1C(CN(C1C(=O)O)C(=O)CN)NC(=O)C2=CC=CC=C2

GAP-134 (Cat No.:I005610) is a small peptide compound known as a gap junction enhancer. It selectively enhances the function of gap junctions, specialized protein channels that facilitate direct communication between adjacent cells. By improving intercellular communication, GAP-134 has the potential to influence cellular signaling and coordination. This compound has been studied for its therapeutic applications, particularly in cardiovascular and neurological conditions, where enhancing gap junction coupling may have beneficial effects. GAP-134 represents a promising avenue for research into novel treatments that target intercellular communication pathways.

Reference

[1]. De Vuyst E, Boengler K, Antoons G, et al. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology. Br J Pharmacol. 2011 Jun;163(3):469-83.


[2]. Laurent G, Leong-Poi H, Mangat I, et al. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. Circ Arrhythm Electrophysiol. 2009 Apr;2(2):171-8. 


[3]. Hennan JK, Swillo RE, Morgan GA, et al. GAP-134 ([2S,4R]-1-[2-aminoacetyl]4-benzamidopyrrolidine-2-carboxylic acid) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Cardiovasc Pharmacol Ther. 2009 Sep;14(3):207-14.


[4]. Rossman EI, Liu K, Morgan GA, et al. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33.


[5]. Eugene L. Piatnitski Cheklera, John A. Buterab, Li Dib, Discovery of a class of potent gap-junction modifiers as novel antiarrhythmic agents. Bioorganic & Medicinal Chemistry Letters. 2009,19(16): 4551-4554